Gene Uenishi

Gene Uenishi is a Senior Scientist in the Discovery group at GentiBio. Prior to joining GentiBio, Gene was a Scientist at BlueRock Therapeutics, where he developed the iPSC-derived Treg program and helped establish the research group in Boston, MA. He started his career in industry at Casebia Therapeutics working on gene editing HSCs and T-cells to cure rare genetic hematological and autoimmune diseases. During his graduate work, he was a project consultant for Waisman Biomanufacturing assisting with tech transfer for Cynata Therapeutics’ first iPSC-derived mesenchymal stem cell therapy to treat graft-vs-host disease. Gene received his B.A. in psychology from Carleton College and his Ph.D. in Cell and Molecular Pathology from University of Wisconsin – Madison.